Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][8]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including actual market demand and necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 5, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and readiness for launch, leading to investor losses when the truth was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea [4][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Inspire securities between August 6, 2024, and August 4, 2025, alleging that the company made false statements about the demand for its product and the success of its launch [4]. - Allegations include that Inspire failed to disclose poor demand for its device, as providers had surplus inventory and were hesitant to adopt the new treatment [4]. - The company admitted on August 4, 2025, that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers, which affected billing for procedures [5]. Group 2: Financial Impact - Following the announcement of the launch issues and reduced earnings guidance by over 80%, Inspire's share price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 on August 5, 2025 [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the launch and performance of its Inspire V Device, which has reportedly underperformed in the market [1][3][4]. Company Overview - Inspire Medical Systems, Inc. is a medical technology company that develops and manufactures an implantable device for treating obstructive sleep apnea, known as the Inspire V Device [1][3]. Allegations and Issues - The lawsuit claims that the company misrepresented the potential of the Inspire V Device, which was marketed as groundbreaking but faced poor demand and significant inventory issues among providers [3][4]. - Key failures cited include inadequate training for treatment centers, lack of essential IT systems, and unpreparedness for insurance claims processing, which were critical for a successful product launch [4]. Financial Impact - On August 4, 2025, the company announced a significant reduction in its 2025 earnings guidance by over 80%, dropping from a range of $2.20 to $2.30 per share to just $0.40 to $0.50 per share [5]. - Following this announcement, the stock price plummeted by $42.04 per share, a decline of more than 32%, resulting in a loss of $1.2 billion in market capitalization in a single day [5]. - From a high of $216.71 per share on September 23, 2024, the stock has decreased by nearly 60%, erasing billions from the company's market capitalization [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant decline in stock price [1][5]. Company Overview - Inspire Medical Systems, Inc. specializes in implantable neurostimulation technology aimed at improving respiration during sleep [3]. Legal Proceedings - The lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [2][6]. - The lead plaintiff deadline for the lawsuit is set for January 5, 2026 [2]. Allegations - The complaint alleges that the company misrepresented the transition to the Inspire V device as seamless, while in reality, it faced significant operational challenges [3][6]. - Key allegations include poor market demand, incomplete readiness for the launch, and undisclosed logistical issues that hindered the rollout of the Inspire V device [8]. Market Reaction - On August 4, 2025, Inspire Medical publicly acknowledged that the launch of the Inspire V device was facing an "elongated timeframe," leading to a drastic reduction in 2025 earnings guidance by over 80% [4][5]. - Following this announcement, the company's stock price plummeted by over 32% on heavy trading volume [5]. Investigation Focus - Hagens Berman is investigating potential misstatements or omissions related to the Inspire V device launch and its financial implications [7]. - The investigation is particularly focused on whether management was aware of critical operational flaws, such as billing code delays and training deficiencies, prior to the public disclosure [9].

Core Insights - Inspire Medical Systems, Inc. (NYSE:INSP) has recently experienced significant stock performance, reaching a three-month high due to bullish coverage and a price target upgrade from Wolfe Research [1][2] - Wolfe Research upgraded Inspire Medical's rating from "peer perform" to "outperform" with a new price target of $180, indicating a 38% upside potential from its latest closing price [2] - The revision in price target is attributed to updates in Medicare's outpatient payment structure, which will increase payments for Inspire Medical procedures from $30,000 to $45,000 [3] Financial Performance - Inspire Medical reported a net income of $9.9 million for Q3, reflecting a 46% decline from $18.5 million in the same period last year [4] - Despite the decline in net income, revenues increased by 10.5% year-on-year to $224.5 million, driven by a 9% growth in US operations, amounting to $214.4 million [4] - For the full year 2025, the company maintains its revenue guidance of $900 million to $910 million, implying a year-on-year growth of 12 to 13% [5]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors of a timely launch for Inspire V, but failed to adequately prepare clinicians and payors, leading to delays and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - The complaint alleges that the launch of Inspire V was unsuccessful due to poor demand, with providers holding excess inventory and being hesitant to adopt the new treatment [2]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 20 years of experience in complex securities litigation and a dedicated team of more than 70 employees [4].

Core Insights - Inspire Medical Systems' stock has surged due to two key developments: an upgrade from Stifel analyst Jonathan Block and a significant increase in Medicare reimbursement rates for its V implant [2][3] - Despite the recent excitement, the stock is still down 38% year-to-date, indicating potential volatility and risk for investors [2] Financial Performance - Inspire's revenue has grown at an annual rate of 37.7% over the past three years, with a 10.5% year-over-year growth in the last quarter, which is notable for the medical device sector [6] - The company's operating margin is low at 4.2%, compared to the S&P 500's 18.8%, and the net income margin is only 5.0% [6][7] - Operating cash flow margin is a respectable 15.1%, indicating that the company is not depleting cash despite heavy investments for growth [7] Valuation Metrics - Inspire is currently trading at around $115, with a price-to-earnings ratio of 77.2, significantly higher than the S&P 500's 23.0, and a price-to-free cash flow ratio of 34.8 compared to the broader market's 20.2 [5] - The high valuation multiples suggest that investors are paying a premium for growth, which may not be justified given the company's limited profitability [5][11] Balance Sheet Strength - Inspire has a strong financial position with a debt-to-equity ratio of 0.9% and $323 million in cash against only $33 million in debt, providing ample room for continued investment in growth [8] - The market capitalization stands at $3.5 billion, indicating that the company is not at risk of a balance sheet crisis even in challenging market conditions [8] Market Volatility - Inspire's stock has shown significant volatility, dropping 61.6% during the inflation shock of 2022, compared to a 25.4% decline in the S&P 500, and it has not recovered to its 2023 peak of $326 [9][11] - The stock's performance during market downturns suggests that it may amplify losses compared to broader market indices [10] Future Outlook - The Medicare reimbursement increase of 50% could be a turning point for Inspire, potentially leading to higher procedure volumes and improved margins [7][12] - Investors are betting that this reimbursement boost will translate into better financial results, but caution is advised due to the stock's volatility and current valuation [13]